Neutrolis Announces Development Of First-In-Class Treatment Targeting Neutrophil Extracellular Traps (NETs) For Patients With Severe COVID-19
CAMBRIDGE, Mass., Aug. 3, 2020 /PRNewswire/ — Neutrolis, a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cells in the body, today announced the development of NTR-441, a first-in-class DNASE1L3 enzyme analog that has the potential to…
Comments Off on Neutrolis Announces Development Of First-In-Class Treatment Targeting Neutrophil Extracellular Traps (NETs) For Patients With Severe COVID-19